But long-term success on Ozempic, Wegovy, or Mounjaro depends far more on preserving muscle than simply burning calories
Clinically, adding GIP appears to improve both blood sugar control and weight loss outcomes, which is why dual-agonists like Mounjaro outperform single GLP-1 drugs in head-to-head trials
What should I do if I experience severe nausea or vomiting while on semaglutide and COVID-19
The result is a coordinated suppression of appetite and caloric intake that produces clinically significant weight loss in people both with and without type 2 diabetes
Likewise, while SGLT2 inhibitors introduce a new class of drugs, they only offer moderate metabolic control, which does not compare to the efficacy of GLP-1 receptor agonist therapy
Rare forms of diabetes such as Maturity-Onset Diabetes of the Young (MODY) and Latent Autoimmune Diabetes in Adults (LADA) respond differently to treatments